Global NGS-Based RNA-Sequencing Market Size is valued at US$ 3.6 Bn in 2024 and is predicted to reach US$ 20.3 Bn by the year 2034 at an 19.2% CAGR during the forecast period for 2025-2034.
Next-Generation Sequencing (NGS)-based RNA sequencing, or RNA-Seq, is a modern laboratory technique that uses high-throughput sequencing machines to analyze the quantity and sequences of RNA in a biological sample. By converting RNA into DNA and sequencing it, this method provides a comprehensive snapshot of gene activity, showing which genes are turned on or off.
It enables researchers to study gene expression, discover new RNA variants, and identify genetic mutations with a precision and depth that was not possible with older technologies. This makes it a fundamental tool in fields like genomics, cancer research, and drug development.
The NGS-based RNA-sequencing market is expanding due to a number of factors, such as the growing need for targeted therapies as well as personalized medicine, the escalation of chronic illnesses, including cancer and genetic disorders, and the expanding use of RNA-sequencing in drug development.
Furthermore, by facilitating more thorough and accurate analysis of RNA molecules, the introduction of cutting-edge sequencing technologies like single-cell RNA sequencing and nanopore sequencing is anticipated to accelerate the NGS-based RNA-sequencing market expansion further. While boosting the speed and precision of RNA sequencing, Next-Generation Sequencing (NGS) technologies have significantly reduced costs.
As a result, NGS-based RNA-seq is more widely available and appealing for clinical diagnosis and research, which boosts market expansion. Additionally, more genetic research is being done, especially in the fields of infectious diseases, neurology, and cancer. Advances in the study of gene expression, regulation, and splicing are made possible by NGS-based RNA-seq, which is driving the market.
Some of the Key Players in NGS-Based RNA-Sequencing Market:
The NGS-based RNA-sequencing market is segmented by type, workflow component, technology, application, and end-user. By type, the market is segmented into targeted RNA sequencing, mRNA sequencing, total RNA sequencing, single-cell RNA sequencing (scRNA-Seq), de novo transcriptome assembly, and non-coding RNA sequencing (miRNA, lncRNA, circRNA). By workflow component, the market is segmented into sequencing, library preparation & sample processing, storage & cloud bioinformatics, and data analysis & interpretation. In technology, the market is segmented into sequencing by synthesis (SBS), third-generation sequencing (PacBio, ONT), ion semiconductor sequencing, nanopore sequencing (Oxford Nanopore), and SOLiD & pyrosequencing (legacy/declining). The application segment comprises precision medicine, drug discovery & development, cancer genomics, disease mechanism studies, biomarker discovery, single-cell transcriptomics in immuno-oncology, and plant and microbial transcriptomics. By end-user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, contract research organizations (CROs), government and non-profit organizations, and clinical & diagnostic laboratories.
The sequencing category led the NGS-based RNA sequencing market in 2024. This is explained by the growing use of high-throughput sequencing technologies, which offer quick and thorough insights into transcriptome profiles and gene expression. New developments in sequencing technologies that provide increased cost-effectiveness, scalability, and precision are also driving the boom. In oncology, neurology, and personalized medicine, the need for next-generation sequencing technology has increased along with research and clinical applications. Furthermore, the sequencing segment's leading position in the market has been cemented by its capacity to sequence a broad variety of RNA molecules, such as mRNA, non-coding RNAs, and splice variants.
The NGS-based RNA-sequencing market was dominated by medication development and discovery. This is because RNA-seq technologies are increasingly being used to accelerate the discovery of new therapeutic targets, define disease mechanisms, and find biomarkers. In oncology, neurology, and immunology in particular, RNA-sequencing facilitates more accurate gene expression profiling, which aids in the creation of tailored treatments. It is now crucial for pharmaceutical companies to incorporate RNA-seq data into their drug discovery pipelines as their focus shifts to personalized treatment. Its dominance in the drug development industry is further supported by RNA-seq's contribution to bettering medication efficacy and clinical trial design.
North America dominated the largest share of the NGS-based RNA sequencing market. The region's early adoption of cutting-edge genomic technologies, substantial research funding, and strong presence of top sequencing technology businesses are the main drivers of this dominance. The United States has a strong healthcare system, several genomics research projects, and the presence of major companies, which contributes to its majority of the market share. Furthermore, the U.S.'s increasing focus on tailored therapeutics and precision medicine has sped up the use of RNA sequencing technologies.
The NGS-based RNA sequencing market is expanding very fast in the Asia-Pacific region over the forecast period. Growing government investments in biotechnology, the expansion of the healthcare system, and the rise in chronic diseases that call for sophisticated diagnostic tools are all factors contributing to this quick growth. Moreover, the demand for RNA sequencing technologies is also being driven by these nations' expanding middle classes and increased awareness of precision medicine, which makes Asia-Pacific a crucial area for market expansion.
NGS-Based RNA-Sequencing Market by Type-
· Targeted RNA Sequencing
· mRNA Sequencing
· Total RNA Sequencing
· Single-cell RNA Sequencing (scRNA-Seq)
· De Novo Transcriptome Assembly
· Non-coding RNA Sequencing (miRNA, lncRNA, circRNA)
NGS-Based RNA-Sequencing Market by Workflow Component -
· Sequencing
· Library Preparation & Sample Processing
· Storage & Cloud Bioinformatics
· Data Analysis & Interpretation
NGS-Based RNA-Sequencing Market by Technology-
· Sequencing by Synthesis (SBS)
· Third-generation Sequencing (PacBio, ONT)
· Ion Semiconductor Sequencing
· Nanopore Sequencing (Oxford Nanopore)
· SOLiD & Pyrosequencing (legacy/declining)
NGS-Based RNA-Sequencing Market by Application-
· Precision Medicine
· Drug Discovery & Development
· Cancer Genomics
· Disease Mechanism Studies
· Biomarker Discovery
· Single-Cell Transcriptomics in Immuno-Oncology
· Plant and Microbial Transcriptomics
NGS-Based RNA-Sequencing Market by End-user-
· Pharmaceutical & Biotechnology Companies
· Academic & Research Institutions
· Contract Research Organizations (CROs)
· Government and Non-profit Organizations
· Clinical & Diagnostic Laboratories
NGS-Based RNA-Sequencing Market by Region-
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global NGS-Based RNA-Sequencing Market Snapshot
Chapter 4. Global NGS-Based RNA-Sequencing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on NGS-Based RNA-Sequencing Market Industry Trends
4.10. Global NGS-Based RNA-Sequencing Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
Chapter 5. NGS-Based RNA-Sequencing Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. mRNA Sequencing
5.2.1.1. Analysis of coding transcripts, widely used in disease research
5.2.2. Total RNA Sequencing
5.2.3. Targeted RNA Sequencing
5.2.4. Single-cell RNA Sequencing (scRNA-Seq)
5.2.4.1. Enables high-resolution transcriptomic profiling of individual cells
5.2.5. Non-coding RNA Sequencing (miRNA, lncRNA, circRNA)
5.2.6. De Novo Transcriptome Assembly
Chapter 6. NGS-Based RNA-Sequencing Market Segmentation 2: By End-User, Estimates & Trend Analysis
6.1. Market Share by End-User, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
6.2.1. Academic & Research Institutions
6.2.2. Pharmaceutical & Biotechnology Companies
6.2.3. Contract Research Organizations (CROs)
6.2.4. Clinical & Diagnostic Laboratories
6.2.5. Government and Non-profit Organizations
Chapter 7. NGS-Based RNA-Sequencing Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Drug Discovery & Development
7.2.2. Disease Mechanism Studies
7.2.3. Biomarker Discovery
7.2.4. Precision Medicine
7.2.5. Cancer Genomics
7.2.6. Single-Cell Transcriptomics in Immuno-Oncology
7.2.7. Plant and Microbial Transcriptomics
Chapter 8. NGS-Based RNA-Sequencing Market Segmentation 4: By Workflow Component, Estimates & Trend Analysis
8.1. Market Share by Workflow Component, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Workflow Component:
8.2.1. Library Preparation & Sample Processing
8.2.2. Sequencing
8.2.3. Data Analysis & Interpretation
8.2.4. Storage & Cloud Bioinformatics
Chapter 9. NGS-Based RNA-Sequencing Market Segmentation 5: By Technology, Estimates & Trend Analysis
9.1. Market Share by Technology, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
9.2.1. Sequencing by Synthesis (SBS)
9.2.1.1. Illumina platforms, high throughput
9.2.2. Nanopore Sequencing (Oxford Nanopore)
9.2.3. Ion Semiconductor Sequencing
9.2.4. Third-generation Sequencing (PacBio, ONT)
9.2.5. SOLiD & Pyrosequencing (legacy/declining)
Chapter 10. NGS-Based RNA-Sequencing Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global NGS-Based RNA-Sequencing Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.2.3. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.2.4. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.2.5. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
10.2.6. North America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
10.3. Europe
10.3.1. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3.3. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3.4. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.3.5. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
10.3.6. Europe NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.4.3. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4.4. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.4.5. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
10.4.6. Asia Pacific NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
10.5. Latin America
10.5.1. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5.3. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5.4. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.5.5. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
10.5.6. Latin America NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6.3. Middle East & Africa NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.6.4. Middle East & Africa NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.6.5. Middle East & Africa NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
10.6.6. Middle East & Africa NGS-Based RNA-Sequencing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Illumina, Inc.
11.2.1.1. Business Overview
11.2.1.2. Key Type/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Thermo Fisher Scientific
11.2.3. Oxford Nanopore Technologies
11.2.4. Pacific Biosciences (PacBio)
11.2.5. Agilent Technologies
11.2.6. QIAGEN
11.2.7. Takara Bio Inc.
11.2.8. 10x Genomics
11.2.9. BGI Genomics
11.2.10. PerkinElmer (Revvity)
11.2.11. CD Genomics
11.2.12. Novogene Corporation
11.2.13. Eurofins Genomics
11.2.14. Fulgent Genetics
11.2.15. Macrogen Inc.
11.2.16. Bio-Rad Laboratories
11.2.17. Genewiz (Azenta Life Sciences)
11.2.18. Parse Biosciences
11.2.19. Element Biosciences